Zealand Pharma A/S

Zealand announces total number of shares and voting rights in the company as of 30 June 2015

Phase I trial results for Zealand’s glucagon analogue, ZP4207 support its further development as a ready-to-use rescue treatment for severe hypoglycemia in diabetes patients on insulin therapy

Major shareholder announcement

Zealand announces an amendment to its Articles of Association to reflect an increase in share capital after exercise of employee warrants

Zealand increases its share capital after exercise of employee warrants

Major shareholder announcement

Zealand informs of updates given by Sanofi on Lyxumia® and LixiLan on an IR Thematic Conference Call on Diabetes

Zealand informs that data presented from the ELIXA study establish Lyxumia® as the first GLP-1 receptor agonist with cardiovascular safety proven in a long-term outcome trial

Presentations on two novel Zealand preclinical peptide therapeutics as possible approaches for the treatment of Type 2 diabetes and obesity at the American Diabetes Association’s (ADA) 74th Scientific Sessions

Zealand announces that Sanofi has informed of results from GetGoal Duo-2, showing advantages of Lyxumia® versus rapid-acting insulin as add-on to Lantus® for the treatment of Type 2 diabetes

Zealand increases the share capital after exercise of employee warrants and announces an amendment to its Articles of Association

New data on lixisenatide (Lyxumia®) including ELIXA results on LixiLan, and on novel Zealand peptide therapeutics, to be presented at the American Diabetes Association’s (ADA) 75th Scientific Sessions

Zealand presents to investors at four conferences in June 2015

Zealand Interim Report for Q1 2015 (unaudited) Increase in royalty revenue and progression of the development pipeline

Zealand starts clinical development of a multiple-dose version of its stable glucagon analogue, ZP4207

Notice of Zealand’s Interim Report for Q1 2015 and related conference call

Zealand announces an amendment to its Articles of Association following grant of warrants

Zealand announces grants of new warrants under employee warrant programs and reports of transactions in the company’s shares and related securities by managerial employees and their related parties

Zealand gives three presentations at the American TIDES 2015 conference – including as keynote speaker

Zealand announces total number of shares and voting rights in the company as of 30 April 2015

Zealand reports Lyxumia® royalty revenue for Q1 2015

Major shareholder announcement

Passing of Zealand’s Annual General Meeting in 2015

Zealand announces an amendment to its Articles of Association to reflect an increase in share capital after exercise of employee warrants

Zealand increases the share capital after exercise of employee warrants

Zealand convenes for the Annual General Meeting 2015

Zealand announces an amendment to its Articles of Association to reflect grant of warrants

Zealand announces the grant of warrants under existing warrant scheme

CORRECTION: Zealand announces an amendment to its Articles of Association to reflect an increase in share capital after exercise of employee warrants

Zealand announces an amendment to its Articles of Association to reflect an increase in share capital after exercise of employee warrants